Global Next-Generation Gynecological Cancer Diagnostics Market Research Report 2024

Report ID: 1919319 | Published Date: Jan 2025 | No. of Page: 95 | Base Year: 2024 | Rating: 3.7 | Webstory: Check our Web story
Request Sample Report
Pre-Order Enquiry
Request Discount(%) 
1 Report Overview
    1.1 Study Scope
    1.2 Market Analysis by Type
        1.2.1 Global Next-Generation Gynecological Cancer Diagnostics Market Size Growth Rate by Type: 2017 VS 2021 VS 2028
        1.2.2 Ovarian Cancer Diagnosis
        1.2.3 Cervical Cancer Diagnosis
        1.2.4 Uterine Cancer Diagnosis
    1.3 Market by Application
        1.3.1 Global Next-Generation Gynecological Cancer Diagnostics Market Share by Application: 2017 VS 2021 VS 2028
        1.3.2 Hospitals
        1.3.3 Clinics
        1.3.4 Others
    1.4 Study Objectives
    1.5 Years Considered
2 Global Growth Trends
    2.1 Global Next-Generation Gynecological Cancer Diagnostics Market Perspective (2017-2028)
    2.2 Next-Generation Gynecological Cancer Diagnostics Growth Trends by Region
        2.2.1 Next-Generation Gynecological Cancer Diagnostics Market Size by Region: 2017 VS 2021 VS 2028
        2.2.2 Next-Generation Gynecological Cancer Diagnostics Historic Market Size by Region (2017-2022)
        2.2.3 Next-Generation Gynecological Cancer Diagnostics Forecasted Market Size by Region (2023-2028)
    2.3 Next-Generation Gynecological Cancer Diagnostics Market Dynamics
        2.3.1 Next-Generation Gynecological Cancer Diagnostics Industry Trends
        2.3.2 Next-Generation Gynecological Cancer Diagnostics Market Drivers
        2.3.3 Next-Generation Gynecological Cancer Diagnostics Market Challenges
        2.3.4 Next-Generation Gynecological Cancer Diagnostics Market Restraints
3 Competition Landscape by Key Players
    3.1 Global Top Next-Generation Gynecological Cancer Diagnostics Players by Revenue
        3.1.1 Global Top Next-Generation Gynecological Cancer Diagnostics Players by Revenue (2017-2022)
        3.1.2 Global Next-Generation Gynecological Cancer Diagnostics Revenue Market Share by Players (2017-2022)
    3.2 Global Next-Generation Gynecological Cancer Diagnostics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
    3.3 Players Covered: Ranking by Next-Generation Gynecological Cancer Diagnostics Revenue
    3.4 Global Next-Generation Gynecological Cancer Diagnostics Market Concentration Ratio
        3.4.1 Global Next-Generation Gynecological Cancer Diagnostics Market Concentration Ratio (CR5 and HHI)
        3.4.2 Global Top 10 and Top 5 Companies by Next-Generation Gynecological Cancer Diagnostics Revenue in 2021
    3.5 Next-Generation Gynecological Cancer Diagnostics Key Players Head office and Area Served
    3.6 Key Players Next-Generation Gynecological Cancer Diagnostics Product Solution and Service
    3.7 Date of Enter into Next-Generation Gynecological Cancer Diagnostics Market
    3.8 Mergers & Acquisitions, Expansion Plans
4 Next-Generation Gynecological Cancer Diagnostics Breakdown Data by Type
    4.1 Global Next-Generation Gynecological Cancer Diagnostics Historic Market Size by Type (2017-2022)
    4.2 Global Next-Generation Gynecological Cancer Diagnostics Forecasted Market Size by Type (2023-2028)
5 Next-Generation Gynecological Cancer Diagnostics Breakdown Data by Application
    5.1 Global Next-Generation Gynecological Cancer Diagnostics Historic Market Size by Application (2017-2022)
    5.2 Global Next-Generation Gynecological Cancer Diagnostics Forecasted Market Size by Application (2023-2028)
6 North America
    6.1 North America Next-Generation Gynecological Cancer Diagnostics Market Size (2017-2028)
    6.2 North America Next-Generation Gynecological Cancer Diagnostics Market Size by Country (2017-2022)
    6.3 North America Next-Generation Gynecological Cancer Diagnostics Market Size by Country (2023-2028)
    6.4 United States
    6.5 Canada
7 Europe
    7.1 Europe Next-Generation Gynecological Cancer Diagnostics Market Size (2017-2028)
    7.2 Europe Next-Generation Gynecological Cancer Diagnostics Market Size by Country (2017-2022)
    7.3 Europe Next-Generation Gynecological Cancer Diagnostics Market Size by Country (2023-2028)
    7.4 Germany
    7.5 France
    7.6 U.K.
    7.7 Italy
    7.8 Russia
    7.9 Nordic Countries
8 Asia-Pacific
    8.1 Asia-Pacific Next-Generation Gynecological Cancer Diagnostics Market Size (2017-2028)
    8.2 Asia-Pacific Next-Generation Gynecological Cancer Diagnostics Market Size by Country (2017-2022)
    8.3 Asia-Pacific Next-Generation Gynecological Cancer Diagnostics Market Size by Country (2023-2028)
    8.4 China
    8.5 Japan
    8.6 South Korea
    8.7 Southeast Asia
    8.8 India
    8.9 Australia
9 Latin America
    9.1 Latin America Next-Generation Gynecological Cancer Diagnostics Market Size (2017-2028)
    9.2 Latin America Next-Generation Gynecological Cancer Diagnostics Market Size by Country (2017-2022)
    9.3 Latin America Next-Generation Gynecological Cancer Diagnostics Market Size by Country (2023-2028)
    9.4 Mexico
    9.5 Brazil
10 Middle East & Africa
    10.1 Middle East & Africa Next-Generation Gynecological Cancer Diagnostics Market Size (2017-2028)
    10.2 Middle East & Africa Next-Generation Gynecological Cancer Diagnostics Market Size by Country (2017-2022)
    10.3 Middle East & Africa Next-Generation Gynecological Cancer Diagnostics Market Size by Country (2023-2028)
    10.4 Turkey
    10.5 Saudi Arabia
    10.6 UAE
11 Key Players Profiles
    11.1 Quest Diagnostics Incorporated
        11.1.1 Quest Diagnostics Incorporated Company Detail
        11.1.2 Quest Diagnostics Incorporated Business Overview
        11.1.3 Quest Diagnostics Incorporated Next-Generation Gynecological Cancer Diagnostics Introduction
        11.1.4 Quest Diagnostics Incorporated Revenue in Next-Generation Gynecological Cancer Diagnostics Business (2017-2022)
        11.1.5 Quest Diagnostics Incorporated Recent Development
    11.2 Thermo Fisher Scientific Inc.
        11.2.1 Thermo Fisher Scientific Inc. Company Detail
        11.2.2 Thermo Fisher Scientific Inc. Business Overview
        11.2.3 Thermo Fisher Scientific Inc. Next-Generation Gynecological Cancer Diagnostics Introduction
        11.2.4 Thermo Fisher Scientific Inc. Revenue in Next-Generation Gynecological Cancer Diagnostics Business (2017-2022)
        11.2.5 Thermo Fisher Scientific Inc. Recent Development
    11.3 Agilent Technologies, Inc.
        11.3.1 Agilent Technologies, Inc. Company Detail
        11.3.2 Agilent Technologies, Inc. Business Overview
        11.3.3 Agilent Technologies, Inc. Next-Generation Gynecological Cancer Diagnostics Introduction
        11.3.4 Agilent Technologies, Inc. Revenue in Next-Generation Gynecological Cancer Diagnostics Business (2017-2022)
        11.3.5 Agilent Technologies, Inc. Recent Development
    11.4 Invitae Corporation
        11.4.1 Invitae Corporation Company Detail
        11.4.2 Invitae Corporation Business Overview
        11.4.3 Invitae Corporation Next-Generation Gynecological Cancer Diagnostics Introduction
        11.4.4 Invitae Corporation Revenue in Next-Generation Gynecological Cancer Diagnostics Business (2017-2022)
        11.4.5 Invitae Corporation Recent Development
    11.5 Konica Minolta, Inc.
        11.5.1 Konica Minolta, Inc. Company Detail
        11.5.2 Konica Minolta, Inc. Business Overview
        11.5.3 Konica Minolta, Inc. Next-Generation Gynecological Cancer Diagnostics Introduction
        11.5.4 Konica Minolta, Inc. Revenue in Next-Generation Gynecological Cancer Diagnostics Business (2017-2022)
        11.5.5 Konica Minolta, Inc. Recent Development
    11.6 BGI Genomics
        11.6.1 BGI Genomics Company Detail
        11.6.2 BGI Genomics Business Overview
        11.6.3 BGI Genomics Next-Generation Gynecological Cancer Diagnostics Introduction
        11.6.4 BGI Genomics Revenue in Next-Generation Gynecological Cancer Diagnostics Business (2017-2022)
        11.6.5 BGI Genomics Recent Development
    11.7 CENTOGENE N.V.
        11.7.1 CENTOGENE N.V. Company Detail
        11.7.2 CENTOGENE N.V. Business Overview
        11.7.3 CENTOGENE N.V. Next-Generation Gynecological Cancer Diagnostics Introduction
        11.7.4 CENTOGENE N.V. Revenue in Next-Generation Gynecological Cancer Diagnostics Business (2017-2022)
        11.7.5 CENTOGENE N.V. Recent Development
    11.8 Fulgent Genetics, Inc.
        11.8.1 Fulgent Genetics, Inc. Company Detail
        11.8.2 Fulgent Genetics, Inc. Business Overview
        11.8.3 Fulgent Genetics, Inc. Next-Generation Gynecological Cancer Diagnostics Introduction
        11.8.4 Fulgent Genetics, Inc. Revenue in Next-Generation Gynecological Cancer Diagnostics Business (2017-2022)
        11.8.5 Fulgent Genetics, Inc. Recent Development
    11.9 Illumina, Inc.
        11.9.1 Illumina, Inc. Company Detail
        11.9.2 Illumina, Inc. Business Overview
        11.9.3 Illumina, Inc. Next-Generation Gynecological Cancer Diagnostics Introduction
        11.9.4 Illumina, Inc. Revenue in Next-Generation Gynecological Cancer Diagnostics Business (2017-2022)
        11.9.5 Illumina, Inc. Recent Development
    11.10 F. Hoffmann-La Roche Ltd
        11.10.1 F. Hoffmann-La Roche Ltd Company Detail
        11.10.2 F. Hoffmann-La Roche Ltd Business Overview
        11.10.3 F. Hoffmann-La Roche Ltd Next-Generation Gynecological Cancer Diagnostics Introduction
        11.10.4 F. Hoffmann-La Roche Ltd Revenue in Next-Generation Gynecological Cancer Diagnostics Business (2017-2022)
        11.10.5 F. Hoffmann-La Roche Ltd Recent Development
    11.11 Laboratory Corporation of America Holdings
        11.11.1 Laboratory Corporation of America Holdings Company Detail
        11.11.2 Laboratory Corporation of America Holdings Business Overview
        11.11.3 Laboratory Corporation of America Holdings Next-Generation Gynecological Cancer Diagnostics Introduction
        11.11.4 Laboratory Corporation of America Holdings Revenue in Next-Generation Gynecological Cancer Diagnostics Business (2017-2022)
        11.11.5 Laboratory Corporation of America Holdings Recent Development
    11.12 ARUP Laboratories
        11.12.1 ARUP Laboratories Company Detail
        11.12.2 ARUP Laboratories Business Overview
        11.12.3 ARUP Laboratories Next-Generation Gynecological Cancer Diagnostics Introduction
        11.12.4 ARUP Laboratories Revenue in Next-Generation Gynecological Cancer Diagnostics Business (2017-2022)
        11.12.5 ARUP Laboratories Recent Development
    11.13 Myriad Genetics, Inc.
        11.13.1 Myriad Genetics, Inc. Company Detail
        11.13.2 Myriad Genetics, Inc. Business Overview
        11.13.3 Myriad Genetics, Inc. Next-Generation Gynecological Cancer Diagnostics Introduction
        11.13.4 Myriad Genetics, Inc. Revenue in Next-Generation Gynecological Cancer Diagnostics Business (2017-2022)
        11.13.5 Myriad Genetics, Inc. Recent Development
    11.14 OPKO Health, Inc.
        11.14.1 OPKO Health, Inc. Company Detail
        11.14.2 OPKO Health, Inc. Business Overview
        11.14.3 OPKO Health, Inc. Next-Generation Gynecological Cancer Diagnostics Introduction
        11.14.4 OPKO Health, Inc. Revenue in Next-Generation Gynecological Cancer Diagnostics Business (2017-2022)
        11.14.5 OPKO Health, Inc. Recent Development
    11.15 QIAGEN N.V.
        11.15.1 QIAGEN N.V. Company Detail
        11.15.2 QIAGEN N.V. Business Overview
        11.15.3 QIAGEN N.V. Next-Generation Gynecological Cancer Diagnostics Introduction
        11.15.4 QIAGEN N.V. Revenue in Next-Generation Gynecological Cancer Diagnostics Business (2017-2022)
        11.15.5 QIAGEN N.V. Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
    13.1 Research Methodology
        13.1.1 Methodology/Research Approach
        13.1.2 Data Source
    13.2 Disclaimer
    13.3 Author Details

List of Tables
    Table 1. Global Next-Generation Gynecological Cancer Diagnostics Market Size Growth Rate by Type (US$ Million): 2017 VS 2021 VS 2028
    Table 2. Key Players of Ovarian Cancer Diagnosis
    Table 3. Key Players of Cervical Cancer Diagnosis
    Table 4. Key Players of Uterine Cancer Diagnosis
    Table 5. Global Next-Generation Gynecological Cancer Diagnostics Market Size Growth by Application (US$ Million): 2017 VS 2021 VS 2028
    Table 6. Global Next-Generation Gynecological Cancer Diagnostics Market Size by Region (US$ Million): 2017 VS 2021 VS 2028
    Table 7. Global Next-Generation Gynecological Cancer Diagnostics Market Size by Region (2017-2022) & (US$ Million)
    Table 8. Global Next-Generation Gynecological Cancer Diagnostics Market Share by Region (2017-2022)
    Table 9. Global Next-Generation Gynecological Cancer Diagnostics Forecasted Market Size by Region (2023-2028) & (US$ Million)
    Table 10. Global Next-Generation Gynecological Cancer Diagnostics Market Share by Region (2023-2028)
    Table 11. Next-Generation Gynecological Cancer Diagnostics Market Trends
    Table 12. Next-Generation Gynecological Cancer Diagnostics Market Drivers
    Table 13. Next-Generation Gynecological Cancer Diagnostics Market Challenges
    Table 14. Next-Generation Gynecological Cancer Diagnostics Market Restraints
    Table 15. Global Next-Generation Gynecological Cancer Diagnostics Revenue by Players (2017-2022) & (US$ Million)
    Table 16. Global Next-Generation Gynecological Cancer Diagnostics Market Share by Players (2017-2022)
    Table 17. Global Top Next-Generation Gynecological Cancer Diagnostics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Next-Generation Gynecological Cancer Diagnostics as of 2021)
    Table 18. Ranking of Global Top Next-Generation Gynecological Cancer Diagnostics Companies by Revenue (US$ Million) in 2021
    Table 19. Global 5 Largest Players Market Share by Next-Generation Gynecological Cancer Diagnostics Revenue (CR5 and HHI) & (2017-2022)
    Table 20. Key Players Headquarters and Area Served
    Table 21. Key Players Next-Generation Gynecological Cancer Diagnostics Product Solution and Service
    Table 22. Date of Enter into Next-Generation Gynecological Cancer Diagnostics Market
    Table 23. Mergers & Acquisitions, Expansion Plans
    Table 24. Global Next-Generation Gynecological Cancer Diagnostics Market Size by Type (2017-2022) & (US$ Million)
    Table 25. Global Next-Generation Gynecological Cancer Diagnostics Revenue Market Share by Type (2017-2022)
    Table 26. Global Next-Generation Gynecological Cancer Diagnostics Forecasted Market Size by Type (2023-2028) & (US$ Million)
    Table 27. Global Next-Generation Gynecological Cancer Diagnostics Revenue Market Share by Type (2023-2028)
    Table 28. Global Next-Generation Gynecological Cancer Diagnostics Market Size by Application (2017-2022) & (US$ Million)
    Table 29. Global Next-Generation Gynecological Cancer Diagnostics Revenue Market Share by Application (2017-2022)
    Table 30. Global Next-Generation Gynecological Cancer Diagnostics Forecasted Market Size by Application (2023-2028) & (US$ Million)
    Table 31. Global Next-Generation Gynecological Cancer Diagnostics Revenue Market Share by Application (2023-2028)
    Table 32. North America Next-Generation Gynecological Cancer Diagnostics Market Size by Country (2017-2022) & (US$ Million)
    Table 33. North America Next-Generation Gynecological Cancer Diagnostics Market Size by Country (2023-2028) & (US$ Million)
    Table 34. Europe Next-Generation Gynecological Cancer Diagnostics Market Size by Country (2017-2022) & (US$ Million)
    Table 35. Europe Next-Generation Gynecological Cancer Diagnostics Market Size by Country (2023-2028) & (US$ Million)
    Table 36. Asia-Pacific Next-Generation Gynecological Cancer Diagnostics Market Size by Region (2017-2022) & (US$ Million)
    Table 37. Asia-Pacific Next-Generation Gynecological Cancer Diagnostics Market Size by Region (2023-2028) & (US$ Million)
    Table 38. Latin America Next-Generation Gynecological Cancer Diagnostics Market Size by Country (2017-2022) & (US$ Million)
    Table 39. Latin America Next-Generation Gynecological Cancer Diagnostics Market Size by Country (2023-2028) & (US$ Million)
    Table 40. Middle East & Africa Next-Generation Gynecological Cancer Diagnostics Market Size by Country (2017-2022) & (US$ Million)
    Table 41. Middle East & Africa Next-Generation Gynecological Cancer Diagnostics Market Size by Country (2023-2028) & (US$ Million)
    Table 42. Quest Diagnostics Incorporated Company Detail
    Table 43. Quest Diagnostics Incorporated Business Overview
    Table 44. Quest Diagnostics Incorporated Next-Generation Gynecological Cancer Diagnostics Product
    Table 45. Quest Diagnostics Incorporated Revenue in Next-Generation Gynecological Cancer Diagnostics Business (2017-2022) & (US$ Million)
    Table 46. Quest Diagnostics Incorporated Recent Development
    Table 47. Thermo Fisher Scientific Inc. Company Detail
    Table 48. Thermo Fisher Scientific Inc. Business Overview
    Table 49. Thermo Fisher Scientific Inc. Next-Generation Gynecological Cancer Diagnostics Product
    Table 50. Thermo Fisher Scientific Inc. Revenue in Next-Generation Gynecological Cancer Diagnostics Business (2017-2022) & (US$ Million)
    Table 51. Thermo Fisher Scientific Inc. Recent Development
    Table 52. Agilent Technologies, Inc. Company Detail
    Table 53. Agilent Technologies, Inc. Business Overview
    Table 54. Agilent Technologies, Inc. Next-Generation Gynecological Cancer Diagnostics Product
    Table 55. Agilent Technologies, Inc. Revenue in Next-Generation Gynecological Cancer Diagnostics Business (2017-2022) & (US$ Million)
    Table 56. Agilent Technologies, Inc. Recent Development
    Table 57. Invitae Corporation Company Detail
    Table 58. Invitae Corporation Business Overview
    Table 59. Invitae Corporation Next-Generation Gynecological Cancer Diagnostics Product
    Table 60. Invitae Corporation Revenue in Next-Generation Gynecological Cancer Diagnostics Business (2017-2022) & (US$ Million)
    Table 61. Invitae Corporation Recent Development
    Table 62. Konica Minolta, Inc. Company Detail
    Table 63. Konica Minolta, Inc. Business Overview
    Table 64. Konica Minolta, Inc. Next-Generation Gynecological Cancer Diagnostics Product
    Table 65. Konica Minolta, Inc. Revenue in Next-Generation Gynecological Cancer Diagnostics Business (2017-2022) & (US$ Million)
    Table 66. Konica Minolta, Inc. Recent Development
    Table 67. BGI Genomics Company Detail
    Table 68. BGI Genomics Business Overview
    Table 69. BGI Genomics Next-Generation Gynecological Cancer Diagnostics Product
    Table 70. BGI Genomics Revenue in Next-Generation Gynecological Cancer Diagnostics Business (2017-2022) & (US$ Million)
    Table 71. BGI Genomics Recent Development
    Table 72. CENTOGENE N.V. Company Detail
    Table 73. CENTOGENE N.V. Business Overview
    Table 74. CENTOGENE N.V. Next-Generation Gynecological Cancer Diagnostics Product
    Table 75. CENTOGENE N.V. Revenue in Next-Generation Gynecological Cancer Diagnostics Business (2017-2022) & (US$ Million)
    Table 76. CENTOGENE N.V. Recent Development
    Table 77. Fulgent Genetics, Inc. Company Detail
    Table 78. Fulgent Genetics, Inc. Business Overview
    Table 79. Fulgent Genetics, Inc. Next-Generation Gynecological Cancer Diagnostics Product
    Table 80. Fulgent Genetics, Inc. Revenue in Next-Generation Gynecological Cancer Diagnostics Business (2017-2022) & (US$ Million)
    Table 81. Fulgent Genetics, Inc. Recent Development
    Table 82. Illumina, Inc. Company Detail
    Table 83. Illumina, Inc. Business Overview
    Table 84. Illumina, Inc. Next-Generation Gynecological Cancer Diagnostics Product
    Table 85. Illumina, Inc. Revenue in Next-Generation Gynecological Cancer Diagnostics Business (2017-2022) & (US$ Million)
    Table 86. Illumina, Inc. Recent Development
    Table 87. F. Hoffmann-La Roche Ltd Company Detail
    Table 88. F. Hoffmann-La Roche Ltd Business Overview
    Table 89. F. Hoffmann-La Roche Ltd Next-Generation Gynecological Cancer Diagnostics Product
    Table 90. F. Hoffmann-La Roche Ltd Revenue in Next-Generation Gynecological Cancer Diagnostics Business (2017-2022) & (US$ Million)
    Table 91. F. Hoffmann-La Roche Ltd Recent Development
    Table 92. Laboratory Corporation of America Holdings Company Detail
    Table 93. Laboratory Corporation of America Holdings Business Overview
    Table 94. Laboratory Corporation of America Holdings Next-Generation Gynecological Cancer DiagnosticsProduct
    Table 95. Laboratory Corporation of America Holdings Revenue in Next-Generation Gynecological Cancer Diagnostics Business (2017-2022) & (US$ Million)
    Table 96. Laboratory Corporation of America Holdings Recent Development
    Table 97. ARUP Laboratories Company Detail
    Table 98. ARUP Laboratories Business Overview
    Table 99. ARUP Laboratories Next-Generation Gynecological Cancer DiagnosticsProduct
    Table 100. ARUP Laboratories Revenue in Next-Generation Gynecological Cancer Diagnostics Business (2017-2022) & (US$ Million)
    Table 101. ARUP Laboratories Recent Development
    Table 102. Myriad Genetics, Inc. Company Detail
    Table 103. Myriad Genetics, Inc. Business Overview
    Table 104. Myriad Genetics, Inc. Next-Generation Gynecological Cancer DiagnosticsProduct
    Table 105. Myriad Genetics, Inc. Revenue in Next-Generation Gynecological Cancer Diagnostics Business (2017-2022) & (US$ Million)
    Table 106. Myriad Genetics, Inc. Recent Development
    Table 107. OPKO Health, Inc. Company Detail
    Table 108. OPKO Health, Inc. Business Overview
    Table 109. OPKO Health, Inc. Next-Generation Gynecological Cancer DiagnosticsProduct
    Table 110. OPKO Health, Inc. Revenue in Next-Generation Gynecological Cancer Diagnostics Business (2017-2022) & (US$ Million)
    Table 111. OPKO Health, Inc. Recent Development
    Table 112. QIAGEN N.V. Company Detail
    Table 113. QIAGEN N.V. Business Overview
    Table 114. QIAGEN N.V. Next-Generation Gynecological Cancer DiagnosticsProduct
    Table 115. QIAGEN N.V. Revenue in Next-Generation Gynecological Cancer Diagnostics Business (2017-2022) & (US$ Million)
    Table 116. QIAGEN N.V. Recent Development
    Table 117. Research Programs/Design for This Report
    Table 118. Key Data Information from Secondary Sources
    Table 119. Key Data Information from Primary Sources
List of Figures
    Figure 1. Global Next-Generation Gynecological Cancer Diagnostics Market Share by Type: 2021 VS 2028
    Figure 2. Ovarian Cancer Diagnosis Features
    Figure 3. Cervical Cancer Diagnosis Features
    Figure 4. Uterine Cancer Diagnosis Features
    Figure 5. Global Next-Generation Gynecological Cancer Diagnostics Market Share by Application in 2021 & 2028
    Figure 6. Hospitals Case Studies
    Figure 7. Clinics Case Studies
    Figure 8. Others Case Studies
    Figure 9. Next-Generation Gynecological Cancer Diagnostics Report Years Considered
    Figure 10. Global Next-Generation Gynecological Cancer Diagnostics Market Size (US$ Million), Year-over-Year: 2017-2028
    Figure 11. Global Next-Generation Gynecological Cancer Diagnostics Market Size, (US$ Million), 2017 VS 2021 VS 2028
    Figure 12. Global Next-Generation Gynecological Cancer Diagnostics Market Share by Region: 2021 VS 2028
    Figure 13. Global Next-Generation Gynecological Cancer Diagnostics Market Share by Players in 2021
    Figure 14. Global Top Next-Generation Gynecological Cancer Diagnostics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Next-Generation Gynecological Cancer Diagnostics as of 2021)
    Figure 15. The Top 10 and 5 Players Market Share by Next-Generation Gynecological Cancer Diagnostics Revenue in 2021
    Figure 16. North America Next-Generation Gynecological Cancer Diagnostics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 17. North America Next-Generation Gynecological Cancer Diagnostics Market Share by Country (2017-2028)
    Figure 18. United States Next-Generation Gynecological Cancer Diagnostics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 19. Canada Next-Generation Gynecological Cancer Diagnostics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 20. Europe Next-Generation Gynecological Cancer Diagnostics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 21. Europe Next-Generation Gynecological Cancer Diagnostics Market Share by Country (2017-2028)
    Figure 22. Germany Next-Generation Gynecological Cancer Diagnostics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 23. France Next-Generation Gynecological Cancer Diagnostics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 24. U.K. Next-Generation Gynecological Cancer Diagnostics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 25. Italy Next-Generation Gynecological Cancer Diagnostics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 26. Russia Next-Generation Gynecological Cancer Diagnostics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 27. Nordic Countries Next-Generation Gynecological Cancer Diagnostics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 28. Asia-Pacific Next-Generation Gynecological Cancer Diagnostics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 29. Asia-Pacific Next-Generation Gynecological Cancer Diagnostics Market Share by Region (2017-2028)
    Figure 30. China Next-Generation Gynecological Cancer Diagnostics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 31. Japan Next-Generation Gynecological Cancer Diagnostics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 32. South Korea Next-Generation Gynecological Cancer Diagnostics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 33. Southeast Asia Next-Generation Gynecological Cancer Diagnostics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 34. India Next-Generation Gynecological Cancer Diagnostics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 35. Australia Next-Generation Gynecological Cancer Diagnostics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 36. Latin America Next-Generation Gynecological Cancer Diagnostics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 37. Latin America Next-Generation Gynecological Cancer Diagnostics Market Share by Country (2017-2028)
    Figure 38. Mexico Next-Generation Gynecological Cancer Diagnostics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 39. Brazil Next-Generation Gynecological Cancer Diagnostics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 40. Middle East & Africa Next-Generation Gynecological Cancer Diagnostics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 41. Middle East & Africa Next-Generation Gynecological Cancer Diagnostics Market Share by Country (2017-2028)
    Figure 42. Turkey Next-Generation Gynecological Cancer Diagnostics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 43. Saudi Arabia Next-Generation Gynecological Cancer Diagnostics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 44. Quest Diagnostics Incorporated Revenue Growth Rate in Next-Generation Gynecological Cancer Diagnostics Business (2017-2022)
    Figure 45. Thermo Fisher Scientific Inc. Revenue Growth Rate in Next-Generation Gynecological Cancer Diagnostics Business (2017-2022)
    Figure 46. Agilent Technologies, Inc. Revenue Growth Rate in Next-Generation Gynecological Cancer Diagnostics Business (2017-2022)
    Figure 47. Invitae Corporation Revenue Growth Rate in Next-Generation Gynecological Cancer Diagnostics Business (2017-2022)
    Figure 48. Konica Minolta, Inc. Revenue Growth Rate in Next-Generation Gynecological Cancer Diagnostics Business (2017-2022)
    Figure 49. BGI Genomics Revenue Growth Rate in Next-Generation Gynecological Cancer Diagnostics Business (2017-2022)
    Figure 50. CENTOGENE N.V. Revenue Growth Rate in Next-Generation Gynecological Cancer Diagnostics Business (2017-2022)
    Figure 51. Fulgent Genetics, Inc. Revenue Growth Rate in Next-Generation Gynecological Cancer Diagnostics Business (2017-2022)
    Figure 52. Illumina, Inc. Revenue Growth Rate in Next-Generation Gynecological Cancer Diagnostics Business (2017-2022)
    Figure 53. F. Hoffmann-La Roche Ltd Revenue Growth Rate in Next-Generation Gynecological Cancer Diagnostics Business (2017-2022)
    Figure 54. Laboratory Corporation of America Holdings Revenue Growth Rate in Next-Generation Gynecological Cancer Diagnostics Business (2017-2022)
    Figure 55. ARUP Laboratories Revenue Growth Rate in Next-Generation Gynecological Cancer Diagnostics Business (2017-2022)
    Figure 56. Myriad Genetics, Inc. Revenue Growth Rate in Next-Generation Gynecological Cancer Diagnostics Business (2017-2022)
    Figure 57. OPKO Health, Inc. Revenue Growth Rate in Next-Generation Gynecological Cancer Diagnostics Business (2017-2022)
    Figure 58. QIAGEN N.V. Revenue Growth Rate in Next-Generation Gynecological Cancer Diagnostics Business (2017-2022)
    Figure 59. Bottom-up and Top-down Approaches for This Report
    Figure 60. Data Triangulation
    Figure 61. Key Executives Interviewed
Please ask for List of Figures. Request Sample Report
Companies Included in Reports:
Quest Diagnostics Incorporated
Thermo Fisher Scientific Inc.
Agilent Technologies, Inc.
Invitae Corporation
Konica Minolta, Inc.
BGI Genomics
CENTOGENE N.V.
Fulgent Genetics, Inc.
Illumina, Inc.
F. Hoffmann-La Roche Ltd
Laboratory Corporation of America Holdings
ARUP Laboratories
Myriad Genetics, Inc.
OPKO Health, Inc.
QIAGEN N.V.
Frequently Asked Questions
Next-Generation Gynecological Cancer Diagnostics report offers great insights of the market and consumer data and their interpretation through various figures and graphs. Report has embedded global market and regional market deep analysis through various research methodologies. The report also offers great competitor analysis of the industries and highlights the key aspect of their business like success stories, market development and growth rate.
Next-Generation Gynecological Cancer Diagnostics report is categorised based on following features:
  1. Global Market Players
  2. Geopolitical regions
  3. Consumer Insights
  4. Technological advancement
  5. Historic and Future Analysis of the Market
Next-Generation Gynecological Cancer Diagnostics report is designed on the six basic aspects of analysing the market, which covers the SWOT and SWAR analysis like strength, weakness, opportunity, threat, aspirations and results. This methodology helps investors to reach on to the desired and correct decision to put their capital into the market.

Related Reports